Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly paclitaxel with or without ramucirumab in metastatic gastric adenocarcinoma after platinum/fluoropyrimidine
jRCT2080221417Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab + paclitaxel with Placebo + paclitaxel (2 arms).
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080221417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221417.